Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 454

1.

A Clinical Feasibility Study To Image Angiogenesis in Patients With Arteriovenous Malformations Using 68Ga-RGD PET/CT.

Lobeek D, Bouwman FCM, Aarntzen EHJG, Molkenboer-Kuenen JDM, Flucke UE, Nguyen HL, Vikkula M, Boon LM, Klein W, Laverman P, Oyen WJG, Boerman OC, Terry SYA, SchultzeKool LJ, Rijpkema M.

J Nucl Med. 2019 Sep 13. pii: jnumed.119.231167. doi: 10.2967/jnumed.119.231167. [Epub ahead of print]

PMID:
31519800
2.

A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancer.

Elekonawo FMK, Lütje S, Franssen GM, Bos DL, Goldenberg DM, Boerman OC, Rijpkema M.

EJNMMI Res. 2019 Sep 4;9(1):86. doi: 10.1186/s13550-019-0551-4.

3.

Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors.

Lütje S, Heskamp S, Franssen GM, Frielink C, Kip A, Hekman M, Fracasso G, Colombatti M, Herrmann K, Boerman OC, Gotthardt M, Rijpkema M.

Theranostics. 2019 May 4;9(10):2924-2938. doi: 10.7150/thno.35274. eCollection 2019.

4.

Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.

Verhoeff SR, van Es SC, Boon E, van Helden E, Angus L, Elias SG, Oosting SF, Aarntzen EH, Brouwers AH, Kwee TC, Heskamp S, Hoekstra OS, Verheul H, van der Veldt AAM, de Vries EGE, Boerman OC, van der Graaf WTA, Oyen WJG, van Herpen CML.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1931-1939. doi: 10.1007/s00259-019-04358-9. Epub 2019 Jun 6.

5.

Monitoring 111In-labelled polyisocyanopeptide (PIC) hydrogel wound dressings in full-thickness wounds.

Op 't Veld RC, Joosten L, van den Boomen OI, Boerman OC, Kouwer P, Middelkoop E, Rowan AE, Jansen JA, Walboomers XF, Wagener FADTG.

Biomater Sci. 2019 Jul 1;7(7):3041-3050. doi: 10.1039/c9bm00661c. Epub 2019 May 22.

PMID:
31115398
6.

In Vitro and In Vivo Characterization of an 18F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing Xenografts.

Lütje S, Franssen GM, Herrmann K, Boerman OC, Rijpkema M, Gotthardt M, Heskamp S.

J Nucl Med. 2019 Jul;60(7):1017-1022. doi: 10.2967/jnumed.118.218941. Epub 2019 Jan 17.

PMID:
30655329
7.

Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models.

Huizing FJ, Hoeben BAW, Franssen GM, Boerman OC, Heskamp S, Bussink J.

Mol Pharm. 2019 Feb 4;16(2):701-708. doi: 10.1021/acs.molpharmaceut.8b00950. Epub 2018 Dec 31.

8.

PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer.

Heskamp S, Wierstra PJ, Molkenboer-Kuenen JDM, Sandker GW, Thordardottir S, Cany J, Olive D, Bussink J, Boerman OC, Dolstra H, Aarntzen EHJG, Hobo WA.

Cancer Immunol Res. 2019 Jan;7(1):150-161. doi: 10.1158/2326-6066.CIR-18-0280. Epub 2018 Nov 20.

PMID:
30459153
9.

Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion.

Hekman MCH, Rijpkema M, Aarntzen EH, Mulder SF, Langenhuijsen JF, Oosterwijk E, Boerman OC, Oyen WJG, Mulders PFA.

Eur Urol. 2018 Sep;74(3):257-260. doi: 10.1016/j.eururo.2018.04.026. Epub 2018 May 3.

PMID:
29730017
10.

Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study.

Hekman MC, Rijpkema M, Muselaers CH, Oosterwijk E, Hulsbergen-Van de Kaa CA, Boerman OC, Oyen WJ, Langenhuijsen JF, Mulders PF.

Theranostics. 2018 Mar 8;8(8):2161-2170. doi: 10.7150/thno.23335. eCollection 2018.

11.

In Vivo Characterization of 4 68Ga-Labeled Multimeric RGD Peptides to Image αvβ3 Integrin Expression in 2 Human Tumor Xenograft Mouse Models.

Lobeek D, Franssen GM, Ma MT, Wester HJ, Decristoforo C, Oyen WJG, Boerman OC, Terry SYA, Rijpkema M.

J Nucl Med. 2018 Aug;59(8):1296-1301. doi: 10.2967/jnumed.117.206979. Epub 2018 Apr 6.

12.

Characterization of 111In-labeled Glucose-Dependent Insulinotropic Polypeptide as a Radiotracer for Neuroendocrine Tumors.

Willekens SMA, Joosten L, Boerman OC, Brom M, Gotthardt M.

Sci Rep. 2018 Feb 13;8(1):2948. doi: 10.1038/s41598-018-21259-3.

13.

Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis.

van der Geest T, Roeleveld DM, Walgreen B, Helsen MM, Nayak TK, Klein C, Hegen M, Storm G, Metselaar JM, van den Berg WB, van der Kraan PM, Laverman P, Boerman OC, Koenders MI.

Rheumatology (Oxford). 2018 Apr 1;57(4):737-747. doi: 10.1093/rheumatology/kex456.

PMID:
29361119
14.

Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer.

Tesselaar MH, Crezee T, Schuurmans I, Gerrits D, Nagarajah J, Boerman OC, van Engen-van Grunsven I, Smit JWA, Netea-Maier RT, Plantinga TS.

J Nucl Med. 2018 May;59(5):780-786. doi: 10.2967/jnumed.117.200675. Epub 2017 Dec 14.

15.

Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.

Lütje S, Gerrits D, Molkenboer-Kuenen JD, Herrmann K, Fracasso G, Colombatti M, Boerman OC, Heskamp S.

J Nucl Med. 2018 Mar;59(3):494-501. doi: 10.2967/jnumed.117.196279. Epub 2017 Nov 16.

16.

Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.

Hekman MCH, Boerman OC, Bos DL, Massuger LFAG, Weil S, Grasso L, Rybinski KA, Oosterwijk E, Mulders PFA, Rijpkema M.

Mol Pharm. 2017 Oct 2;14(10):3457-3463. doi: 10.1021/acs.molpharmaceut.7b00464. Epub 2017 Aug 30.

17.

Preclinical validation of 111In-girentuximab-F(ab')2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts.

Huizing FJ, Hoeben BAW, Franssen G, Lok J, Heskamp S, Oosterwijk E, Boerman OC, Bussink J.

Radiother Oncol. 2017 Sep;124(3):521-525. doi: 10.1016/j.radonc.2017.07.025. Epub 2017 Aug 5.

PMID:
28789809
18.

Non-invasive in vivo determination of viable islet graft volume by 111In-exendin-3.

Eter WA, Van der Kroon I, Andralojc K, Buitinga M, Willekens SMA, Frielink C, Bos D, Joosten L, Boerman OC, Brom M, Gotthardt M.

Sci Rep. 2017 Aug 3;7(1):7232. doi: 10.1038/s41598-017-07815-3.

19.

Intraoperative Imaging Techniques to Support Complete Tumor Resection in Partial Nephrectomy.

Hekman MCH, Rijpkema M, Langenhuijsen JF, Boerman OC, Oosterwijk E, Mulders PFA.

Eur Urol Focus. 2018 Dec;4(6):960-968. doi: 10.1016/j.euf.2017.04.008. Epub 2017 May 12. Review.

PMID:
28753888
20.

Design of Radioiodinated Pharmaceuticals: Structural Features Affecting Metabolic Stability towards in Vivo Deiodination.

Cavina L, van der Born D, Klaren PHM, Feiters MC, Boerman OC, Rutjes FPJT.

European J Org Chem. 2017 Jun 30;2017(24):3387-3414. doi: 10.1002/ejoc.201601638. Epub 2017 Apr 26. Review.

21.

Perfluorocarbon/Gold Loading for Noninvasive in Vivo Assessment of Bone Fillers Using 19F Magnetic Resonance Imaging and Computed Tomography.

Mastrogiacomo S, Dou W, Koshkina O, Boerman OC, Jansen JA, Heerschap A, Srinivas M, Walboomers XF.

ACS Appl Mater Interfaces. 2017 Jul 12;9(27):22149-22159. doi: 10.1021/acsami.7b04075. Epub 2017 Jun 28.

22.

Preclinical evaluation of PAC1 targeting with radiolabeled Maxadilan.

Joosten L, Brom M, Schäfer MKH, Boerman OC, Weihe E, Gotthardt M.

Sci Rep. 2017 May 11;7(1):1751. doi: 10.1038/s41598-017-01852-8.

23.

213Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts.

Nonnekens J, Chatalic KL, Molkenboer-Kuenen JD, Beerens CE, Bruchertseifer F, Morgenstern A, Veldhoven-Zweistra J, Schottelius M, Wester HJ, van Gent DC, van Weerden WM, Boerman OC, de Jong M, Heskamp S.

Cancer Biother Radiopharm. 2017 Mar;32(2):67-73. doi: 10.1089/cbr.2016.2155.

PMID:
28301262
24.

α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.

Heskamp S, Hernandez R, Molkenboer-Kuenen JDM, Essler M, Bruchertseifer F, Morgenstern A, Steenbergen EJ, Cai W, Seidl C, McBride WJ, Goldenberg DM, Boerman OC.

J Nucl Med. 2017 Jun;58(6):926-933. doi: 10.2967/jnumed.116.187021. Epub 2017 Feb 23.

25.

Bisphosphonate-Functionalized Imaging Agents, Anti-Tumor Agents and Nanocarriers for Treatment of Bone Cancer.

Nadar RA, Margiotta N, Iafisco M, van den Beucken JJJP, Boerman OC, Leeuwenburgh SCG.

Adv Healthc Mater. 2017 Apr;6(8). doi: 10.1002/adhm.201601119. Epub 2017 Feb 16. Review.

PMID:
28207199
26.

Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model.

Hekman MCH, Rijpkema M, Bos DL, Oosterwijk E, Goldenberg DM, Mulders PFA, Boerman OC.

J Nucl Med. 2017 May;58(5):706-710. doi: 10.2967/jnumed.116.185470. Epub 2017 Jan 26.

27.

Preventing Radiobleaching of Cyanine Fluorophores Enhances Stability of Nuclear/NIRF Multimodality Imaging Agents.

Hernandez R, Heskamp S, Rijpkema M, Bos DL, Goldenberg DM, McBride WJ, Morgenstern A, Bruchertseifer F, Cai W, Boerman OC.

Theranostics. 2017 Jan 1;7(1):1-8. doi: 10.7150/thno.15124. eCollection 2017.

28.

Quantitative and longitudinal imaging of intramuscular transplanted islets of Langerhans with SPECT using [ 123 I]IBZM.

Willekens SM, van der Kroon I, Bos D, Joosten L, Frielink C, Boerman OC, Brom M, Gotthardt M.

Diabetes Obes Metab. 2017 Apr;19(4):604-608. doi: 10.1111/dom.12857. Epub 2017 Jan 30.

PMID:
27987245
29.

Digitalis-like Compounds Facilitate Non-Medullary Thyroid Cancer Redifferentiation through Intracellular Ca2+, FOS, and Autophagy-Dependent Pathways.

Tesselaar MH, Crezee T, Swarts HG, Gerrits D, Boerman OC, Koenderink JB, Stunnenberg HG, Netea MG, Smit JW, Netea-Maier RT, Plantinga TS.

Mol Cancer Ther. 2017 Jan;16(1):169-181. doi: 10.1158/1535-7163.MCT-16-0460. Epub 2016 Nov 11.

30.

Response Monitoring with [18F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases.

Heskamp S, Heijmen L, Gerrits D, Molkenboer-Kuenen JDM, Ter Voert EGW, Heinzmann K, Honess DJ, Smith DM, Griffiths JR, Doblas S, Sinkus R, Laverman P, Oyen WJG, Heerschap A, Boerman OC.

Mol Imaging Biol. 2017 Aug;19(4):540-549. doi: 10.1007/s11307-016-1021-2.

31.

CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses.

Hutten TJ, Thordardottir S, Fredrix H, Janssen L, Woestenenk R, Tel J, Joosten B, Cambi A, Heemskerk MH, Franssen GM, Boerman OC, Bakker LB, Jansen JH, Schaap N, Dolstra H, Hobo W.

J Immunol. 2016 Oct 1;197(7):2715-25. doi: 10.4049/jimmunol.1600011. Epub 2016 Aug 26.

32.

Improved Quantification of the Beta Cell Mass after Pancreas Visualization with 99mTc-demobesin-4 and Beta Cell Imaging with 111In-exendin-3 in Rodents.

van der Kroon I, Joosten L, Nock BA, Maina T, Boerman OC, Brom M, Gotthardt M.

Mol Pharm. 2016 Oct 3;13(10):3478-3483. Epub 2016 Aug 31.

PMID:
27537699
33.

The effect of purification of Ga-68-labeled exendin on in vivo distribution.

Brom M, Franssen GM, Joosten L, Gotthardt M, Boerman OC.

EJNMMI Res. 2016 Dec;6(1):65. doi: 10.1186/s13550-016-0221-8. Epub 2016 Aug 12.

34.

In Vivo Imaging of Antileukemic Drug Asparaginase Reveals a Rapid Macrophage-Mediated Clearance from the Bone Marrow.

van der Meer LT, Terry SY, van Ingen Schenau DS, Andree KC, Franssen GM, Roeleveld DM, Metselaar JM, Reinheckel T, Hoogerbrugge PM, Boerman OC, van Leeuwen FN.

J Nucl Med. 2017 Feb;58(2):214-220. doi: 10.2967/jnumed.116.177741. Epub 2016 Aug 4.

35.

Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti-Fibroblast Activation Protein Antibody.

van der Geest T, Laverman P, Gerrits D, Walgreen B, Helsen MM, Klein C, Nayak TK, Storm G, Metselaar JM, Koenders MI, Boerman OC.

J Nucl Med. 2017 Jan;58(1):151-155. doi: 10.2967/jnumed.116.177931. Epub 2016 Aug 4.

36.

Radionuclide imaging of liposomal drug delivery.

van der Geest T, Laverman P, Metselaar JM, Storm G, Boerman OC.

Expert Opin Drug Deliv. 2016 Sep;13(9):1231-42. doi: 10.1080/17425247.2016.1205584. Epub 2016 Jul 7. Review.

PMID:
27351233
37.

Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.

Chatalic KL, Heskamp S, Konijnenberg M, Molkenboer-Kuenen JD, Franssen GM, Clahsen-van Groningen MC, Schottelius M, Wester HJ, van Weerden WM, Boerman OC, de Jong M.

Theranostics. 2016 Apr 12;6(6):849-61. doi: 10.7150/thno.14744. eCollection 2016.

38.

Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study.

Hekman MC, Boerman OC, de Weijert M, Bos DL, Oosterwijk E, Langenhuijsen JF, Mulders PF, Rijpkema M.

Clin Cancer Res. 2016 Sep 15;22(18):4634-42. doi: 10.1158/1078-0432.CCR-15-2937. Epub 2016 Apr 21.

39.

Strain Differences Determine the Suitability of Animal Models for Noninvasive In Vivo Beta Cell Mass Determination with Radiolabeled Exendin.

Willekens SM, Joosten L, Boerman OC, Balhuizen A, Eizirik DL, Gotthardt M, Brom M.

Mol Imaging Biol. 2016 Oct;18(5):705-14. doi: 10.1007/s11307-016-0936-y.

40.

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.

Bol KF, Aarntzen EH, Pots JM, Olde Nordkamp MA, van de Rakt MW, Scharenborg NM, de Boer AJ, van Oorschot TG, Croockewit SA, Blokx WA, Oyen WJ, Boerman OC, Mus RD, van Rossum MM, van der Graaf CA, Punt CJ, Adema GJ, Figdor CG, de Vries IJ, Schreibelt G.

Cancer Immunol Immunother. 2016 Mar;65(3):327-39. doi: 10.1007/s00262-016-1796-7. Epub 2016 Feb 10.

41.

Noninvasive Imaging of Islet Transplants with 111In-Exendin-3 SPECT/CT.

van der Kroon I, Andralojc K, Willekens SM, Bos D, Joosten L, Boerman OC, Brom M, Gotthardt M.

J Nucl Med. 2016 May;57(5):799-804. doi: 10.2967/jnumed.115.166330. Epub 2016 Jan 21.

42.

Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.

Muselaers CH, Boers-Sonderen MJ, van Oostenbrugge TJ, Boerman OC, Desar IM, Stillebroer AB, Mulder SF, van Herpen CM, Langenhuijsen JF, Oosterwijk E, Oyen WJ, Mulders PF.

Eur Urol. 2016 May;69(5):767-70. doi: 10.1016/j.eururo.2015.11.033. Epub 2015 Dec 23.

PMID:
26706103
43.

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.

Lütje S, Heskamp S, Cornelissen AS, Poeppel TD, van den Broek SA, Rosenbaum-Krumme S, Bockisch A, Gotthardt M, Rijpkema M, Boerman OC.

Theranostics. 2015 Oct 18;5(12):1388-401. doi: 10.7150/thno.13348. eCollection 2015. Review.

44.

Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin αvβ3.

Terry SY, Koenders MI, Franssen GM, Nayak TK, Freimoser-Grundschober A, Klein C, Oyen WJ, Boerman OC, Laverman P.

J Nucl Med. 2016 Mar;57(3):467-72. doi: 10.2967/jnumed.115.162628. Epub 2015 Dec 3.

45.

99mTc-CXCL8 SPECT to Monitor Disease Activity in Inflammatory Bowel Disease.

Aarntzen EH, Hermsen R, Drenth JP, Boerman OC, Oyen WJ.

J Nucl Med. 2016 Mar;57(3):398-403. doi: 10.2967/jnumed.115.165795. Epub 2015 Nov 25.

46.

SPECT of Transplanted Islets of Langerhans by Dopamine 2 Receptor Targeting in a Rat Model.

Willekens SM, van der Kroon I, Joosten L, Frielink C, Boerman OC, van den Broek SA, Brom M, Gotthardt M.

Mol Pharm. 2016 Jan 4;13(1):85-91. doi: 10.1021/acs.molpharmaceut.5b00518. Epub 2015 Dec 4.

PMID:
26607139
47.

Central delivery of iodine-125-labeled cetuximab, etanercept and anakinra after perispinal injection in rats: possible implications for treating Alzheimer's disease.

Roerink ME, Groen RJ, Franssen G, Lemmers-van de Weem B, Boerman OC, van der Meer JW.

Alzheimers Res Ther. 2015 Nov 12;7(1):70. doi: 10.1186/s13195-015-0149-7.

48.

Comparison of three remote radiolabelling methods for long-circulating liposomes.

van der Geest T, Laverman P, Gerrits D, Franssen GM, Metselaar JM, Storm G, Boerman OC.

J Control Release. 2015 Dec 28;220(Pt A):239-244. doi: 10.1016/j.jconrel.2015.10.043. Epub 2015 Oct 26.

PMID:
26514291
49.

Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy.

Woliner-van der Weg W, Schoffelen R, Hobbs RF, Gotthardt M, Goldenberg DM, Sharkey RM, Slump CH, van der Graaf WT, Oyen WJ, Boerman OC, Sgouros G, Visser EP.

EJNMMI Phys. 2015 Dec;2(1):5. doi: 10.1186/s40658-014-0104-x. Epub 2015 Feb 24.

50.

Graft revascularization is essential for non-invasive monitoring of transplanted islets with radiolabeled exendin.

Eter WA, Bos D, Frielink C, Boerman OC, Brom M, Gotthardt M.

Sci Rep. 2015 Oct 22;5:15521. doi: 10.1038/srep15521.

Supplemental Content

Loading ...
Support Center